Research demonstrates the activity of small molecule inhibitors on tissue transglutaminase, suggesting potential drug applications for various diseases.
Tissue transglutaminase (TG2) is both an enzyme and a G-protein that is implicated in many diseases, such that small molecule inhibitors of TG2 have broad potential as drugs or research tools.
No takes yet. Share an insight, caveat, or question.
Wallace et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: